NZ745187B2 - 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives - Google Patents
3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Download PDFInfo
- Publication number
- NZ745187B2 NZ745187B2 NZ745187A NZ74518717A NZ745187B2 NZ 745187 B2 NZ745187 B2 NZ 745187B2 NZ 745187 A NZ745187 A NZ 745187A NZ 74518717 A NZ74518717 A NZ 74518717A NZ 745187 B2 NZ745187 B2 NZ 745187B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- unsubstituted
- diazaspiro
- methyl
- cis
- propionamide
- Prior art date
Links
- AKFDWOCIAWTVNG-UHFFFAOYSA-N 3-(8-amino-2-oxo-1,3-diazaspiro[4.5]decan-3-yl)propanoic acid Chemical class C(=O)(O)CCN1C(NC2(C1)CCC(CC2)N)=O AKFDWOCIAWTVNG-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims 66
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 39
- -1 oxetanly Chemical group 0.000 claims 39
- 229940080818 propionamide Drugs 0.000 claims 28
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- JDPQWHLMBJZURR-UHFFFAOYSA-N decan-5-one Chemical compound CCCCCC(=O)CCCC JDPQWHLMBJZURR-UHFFFAOYSA-N 0.000 claims 6
- ZAJNGDIORYACQU-UHFFFAOYSA-N methyl n-octyl ketone Natural products CCCCCCCCC(C)=O ZAJNGDIORYACQU-UHFFFAOYSA-N 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical group O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 101100347605 Arabidopsis thaliana VIII-A gene Proteins 0.000 claims 1
- 101100347612 Arabidopsis thaliana VIII-B gene Proteins 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- BSEXNZMHLUMQKR-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1.NC(=O)C1CC1 BSEXNZMHLUMQKR-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Claims (10)
1.Patent claims : 1. A compound according to general formula (I) 13 16 R 14 R wherein R and R independently of one another mean -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, - OH, -OCH , -CN and -CO CH ; 3 2 3 a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, - I, -OH, -OCH , -CN and -CO CH ; wherein said 3membered cycloalkyl moiety is optionally connected 3 2 3 through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH , -CN and -CO CH ; wherein said 3membered heterocycloalkyl moiety is 3 2 3 optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted; R and R together with the nitrogen atom to which they are attached form a ring and mean -(CH ) -; - 2 3-6 (CH ) -O-(CH ) -; or -(CH ) -NR -(CH ) -, wherein R means -H or -C -C -alkyl, linear or branched, 2 2 2 2 2 2 2 2 1 6 saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br and -I; R means -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered cycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubsti- tuted; wherein said 3membered heterocycloalkyl moiety is optionally connected through -C -C - alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6membered aryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; R means -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said -C -C -alkyl is optionally connected through -C(=O)-, -C(=O)O-, or -S(=O) -; 1 6 2 a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered cycloalkyl moiety is optionally connected through -C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3 membered cycloalkyl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH -, or - S(=O) -; a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubsti- tuted; wherein said 3membered heterocycloalkyl moiety is optionally connected through -C -C - alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3membered heterocycloalkyl moiety is optionally connected through -C(=O)-, -C(=O)O-, - C(=O)O-CH2-, or -S(=O)2-; a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6membered aryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6membered aryl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH -, or -S(=O) -; or a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5membered heteroaryl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH -, or -S(=O) -; X means -O-, -S- or -NR -; R means -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered cycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubsti- tuted; wherein said 3membered heterocycloalkyl moiety is optionally connected through -C -C - alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6membered aryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; in case X means NR , R means -C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered cycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubsti- tuted; wherein said 3membered heterocycloalkyl moiety is optionally connected through -C -C - alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6membered aryl moiety is optionally connected through -C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; 6 5 6 or in case X means NR , R and R together with the nitrogen atom to which they are attached form a 3- 12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; 7 8 9 10 11 12 13 14 15 16 17 18 19 20 R , R , R , R , R , R , R , R , R , R , R , R , R , and R independently of one another mean -H, -F, -Cl, -Br, -I, -OH, or -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or R and R together with the carbon atom to which they are attached form a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein "mono- or polysubstituted" means that one or more hydrogen atoms are replaced by a substituent 21 21 independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -R , -C(=O)R , 21 21 22 21 21 -C(=O)OR , -C(=O)NR R , -O-(CH CH -O) -H, -O-(CH CH -O) -CH , =O, -OR , -OC(=O)R , - 2 2 1-30 2 2 1-30 3 21 21 22 21 22 21 22 21 22 OC(=O)OR , -OC(=O)NR R , -NO , -NR R , -NR -(CH ) -C(=O)R , -NR -(CH ) -C(=O)OR , 2 2 1-6 2 1-6 23 21 22 21 22 21 22 23 21 22 -NR -(CH ) -C(=O)NR R , -NR C(=O)R , -NR C(=O)-OR , -NR C(=O)NR R , - 2 1-6 21 22 21 21 21 21 21 22 NR S(=O) R , -SR , -S(=O)R , -S(=O) R , -S(=O) OR , and -S(=O) NR R ; 2 2 2 2 wherein 21 22 23 R , R and R independently of one another mean -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, - CN, -OH, -NH , and -O-C -C -alkyl; 2 1 6 a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3membered cycloalkyl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH , -C -C -alkyl and -O-C -C - 2 1 6 1 6 alkyl; a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3 membered heterocycloalkyl moiety is optionally connected through -C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH , -C -C -alkyl and -O- 2 1 6 C -C -alkyl; a 6membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6membered aryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH , -C -C -alkyl and -O-C -C -alkyl; 2 1 6 1 6 a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH , -C -C -alkyl and -O-C -C - 2 1 6 1 6 alkyl; 21 22 21 22 21 22 21 22 23 21 22 or R and R within -C(=O)NR R , -OC(=O)NR R , -NR R , -NR -(CH ) -C(=O)NR R , - 2 1-6 23 21 22 21 22 NR C(=O)NR R , or -S(=O) NR R together with the nitrogen atom to which they are attached form a ring and mean -(CH ) -; -(CH ) -O-(CH ) -; or -(CH ) -NR -(CH ) -, wherein R means -H or -C -C - 2 3-6 2 2 2 2 2 2 2 2 1 6 alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br and -I; or a physiologically acceptable salt thereof.
2. The compound according to claim 1, wherein (i) R and R independently of one another mean -H or -C - C -alkyl; or (ii) R and R together with the carbon atom to which they are attached form a ring selected from the group consisting of cyclopropyl, cyclobutyl or cyclopentyl, oxetanly, tetrahydrofuranyl or tetrahydropyranyl, in each case unsubstituted. 9 10 11 12 13 14 15 16
3. The compound according to any one of the preceding claims, wherein R , R , R , R , R , R , R , R , 17 18 19 20 R , R , R , and R independently of one another mean -H, -F, -OH, or -C -C -alkyl.
4. The compound according to any one of the preceding claims, wherein (i) R means -H; and R means -C - C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (ii) R means -CH ; and R means -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- 3 1 6 or polysubstituted; or (iii) R means -H or -CH ; and wherein R means -CH -cycloalkyl, -CH -cyclobutyl, 3 2 2 -CH -cyclopentyl, -CH -oxetanyl or -CH -tetrahydrofuranyl; or (iv) R and R together with the nitrogen 2 2 2 atom to which they are attached form a ring and mean -(CH2)3.
5. The compound according to any one of the preceding claims, wherein (i) R means -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (ii) R means a 6 membered aryl moiety, unsubstituted, mono- or polysubstituted; or (iii) R means a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
6. The compound according to any one of the preceding claims, wherein (i) R means -H; or (ii) R means - C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (iii) R means a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3membered cycloalkyl moiety is connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (iv) R means a 3- 12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered heterocycloalkyl moiety is connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (v) R means a 6 membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6membered aryl moiety is connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (vi) R means a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
7. The compound according to any one of the preceding claims, wherein (i) R means -H; or (ii) R means - C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (iii) R means a 3membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted, wherein said 3membered cycloalkyl moiety is optionally connected through -C -C - alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (iv) R means a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3membered heterocycloalkyl moiety is optionally connected through - C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (v) R means a 5membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5membered heteroaryl moiety is optionally connected through -C -C -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. 6 5 6
8. The compound according to any one of the preceding claims, wherein (i) X means NR and R and R together with the nitrogen atom to which they are attached form a 3membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or (ii) X means NR and R means -H or -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
9. The compound according to any one of the preceding claims, which has a structure according to any of general formulas (II-A) to (VIII-C): X N R (II-B) (II-A) X N R (II-C) R (III-A) X N X N 8 7 8 7 R R R R (III-C) (III-B) X N R R 8 7 (CH ) 2 2-3 (CH ) 2 2-3 (IV-A) (IV-B) X N R X N 8 7 (CH ) D 2 2-3 (IV-C) (V-A) X N X N R R R R (V-B) (V-C) X N R R R 8 (CH ) 2 2-3 (CH ) 2 2-3 H CO R 3 H CO (VI-A) (VI-B) X N R (CH ) 2 2-3 (VII-A) (VI-C) X N X N 8 7 8 7 R R R (VII-C) (VII-B) X N R (VIII-A) (VIII-B) (VIII-C) wherein in each case 1 2 3 4 5 6 7 8 R , R , R , R , R , R , R , R , and X are defined as in any one of the preceding claims, R means -H, -OH, -F, -CN or -C -C -alkyl; R means -H or -F; or a physiologically acceptable salt thereof.
10. The compound according to any one of the preceding claims, wherein the substructure has a meaning selected from the group consisting of: HO H N N H N H N H N N N N N N O N O N O N N N N N N NC N O N N CH CH , -CH F, -CHF , -CF , -OCF3, -OH, -OCH , -C(=O)NH , C(=O)NHCH , -C(=O)N(CH ) , -NH , - 2 3 2 2 3 3 2 3 3 2 2 NHCH , -N(CH ) , -NHC(=O)CH , -CH OH, -SOCH and -SO CH ; 3 3 2 3 2 3 2 3 R means -C -C -alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C -C -alkyl; 3membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C - C -alkyl, wherein said 3membered cycloalkyl is connected through -C -C -alkylene; or 4 1 6 3membered heterocycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C - C -alkyl, wherein said 3membered heterocycloalkyl is connected through -C -C -alkylene; 4 1 6 X means -O- or -NR -; R means -C -C -alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, - CN, -O-C -C -alkyl, -C(=O)OH, -C(=O)OC -C -alkyl, -C(=O)NH , -C(=O)NHC -C -alkyl, -C(=O)N(C - 1 4 1 4 2 1 4 1 C -alkyl) , -OH, -S(=O)C -C -alkyl and -S(=O) C -C -alkyl; 4 2 1 4 2 1 4 -cyclobutyl, unsubstituted or monosubstituted with -OH; wherein said -cyclobutyl is connected through - CH -; -heterocyclobutyl, unsubstituted; or -oxazolyl, -pyridinyl, -pyridazinyl or -pyrimidinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, Br, - I, -OH, -O-C -C -alkyl, -CN, and -S(=O) C -C -alkyl; wherein said -oxazolyl, -pyridinyl, -pyridazinyl or - 1 4 2 1 4 pyrimidinyl is optionally connected through -CH -; in case X means NR , R means -H or -CH ; 6 5 6 or in case X means NR , R and R together with the nitrogen atom to which they are attached form a piperidine moiety, a pyrrolidine moiety, a morpholine moiety, a thiomorpholine moiety, a thiomorpholine dioxide moiety, or a piperazine moiety, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of =O, -OH, and - C(=O)NH ; wherein said piperidine moiety, pyrrolidine moiety, morpholine moiety, thiomorpholine moiety, thiomorpholine dioxide moiety, or piperazine moiety is optionally condensed with an imidazole moiety, unsubstituted; R and R independently of one another mean -H or -CH ; or R and R together with the carbon atom to which they are attached form a ring selected from the group consisting of cyclopropyl, cyclobutyl, heterocyclobutyl and heterocyclohexyl, in each case unsubstituted; 9 10 11 12 13 14 15 16 17 18 19 20 R , R , R , R , R , R , R , R , R , R , R , and R mean -H. 12. The compound according to any one of the preceding claims, which has (i) a structure according to general formula (I') 13 16 14 15 X N R 17 20 1 5 7 20 wherein R to R , R to R , and X are defined as in any one of the preceding claims, or a physiologically acceptable salt thereof; or which has (ii) a structure according to general formula (IX) (CH ) 2 1-2 wherein R means -H or -OH; R means -H or -F; R means -H, -CH , or -CH CH -OH; 3 2 2 R means -H or -CH ; and 7 8 7 8 R means -CH and R means -CH ; or R and R together with the carbon atom to which they are attached form a cyclopropyl ring; or a physiologically acceptable salt thereof. 13. The compound according to any one of the preceding claims, which is selected from the group consisting cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-pyridazinyl-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(2- methoxy-pyridinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(6- methoxy-pyridinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(3- methoxy-pyridinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(6- methoxy-pyridazinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(5- methylsulfonyl-pyridinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(5- methoxy-pyridinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(6- methylsulfonyl-pyridinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(6- methoxy-pyrazinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(4- methoxy-pyridinyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N- (oxazolyl-methyl)-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N- (oxazolyl-methyl)-propionamide; cis(Cyclobutyl-methyl)[3-[3,4-dihydroxy-piperidinyl]oxo-propyl]dimethylaminophenyl- 1,3-diazaspiro[4.5]decanone; cis(Cyclobutyl-methyl)[3-[3,4-dihydroxy-pyrrolidinyl]oxo-propyl]dimethylamino phenyl-1,3-diazaspiro[4.5]decanone; cis(Cyclobutyl-methyl)[3-[(3S,4R)-3,4-dihydroxy-pyrrolidinyl]oxo-propyl]dimethylamino- 8-phenyl-1,3-diazaspiro[4.5]decanone; cis(Cyclobutyl-methyl)dimethylamino[3-(3-hydroxy-piperidinyl)oxo-propyl]phenyl-1,3- diazaspiro[4.5]decanone; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-[(1- hydroxy-cyclobutyl)-methyl]-propionamide; cis(Cyclobutyl-methyl)dimethylamino[3-oxo(5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin- 7-yl)-propyl]phenyl-1,3-diazaspiro[4.5]decanone; cis[3-[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]- propanoylamino]-N,N-dimethyl-propionamide; cis-N-(2-Cyano-pyrimidinyl)[8-dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl- 1,3-diazaspiro[4.5]decanyl]-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-pyrimidinyl-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-(4-hydroxy-pyrimidinyl)-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-(4-methoxy-pyrimidinyl)-propionamide; cis[1-(Cyclobutyl-methyl)methylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2- dimethyl-propionamide; cis[1-[(1-Hydroxy-cyclobutyl)-methyl]methylaminooxophenyl-1,3-diazaspiro[4.5]decan yl]-N-(2-hydroxy-ethyl)-propionamide; cis[1-[(1-Hydroxy-cyclobutyl)-methyl]methylaminooxophenyl-1,3-diazaspiro[4.5]decan yl]-propionamide; cis[1-[(1-Hydroxy-cyclobutyl)-methyl]methylaminooxophenyl-1,3-diazaspiro[4.5]decan yl]-N-methyl-propionamide; cis[1-[(1-Hydroxy-cyclobutyl)-methyl]methylaminooxophenyl-1,3-diazaspiro[4.5]decan yl]-N-pyridazinyl-propionamide; cis[8-Dimethylamino(2-methoxy-ethyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(2- hydroxy-ethyl)-propionamide; cis[8-Dimethylamino(2-methoxy-ethyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]-N-methyl- propionamide; cis[8-Dimethylamino(2-methoxy-ethyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]-N- pyrimidinyl-propionamide; cis[8-Dimethylamino(3-methoxy-propyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2- dimethyl-propionamide; cis[8-Dimethylamino(2-methoxy-ethyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2- dimethyl-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-pyridinyl-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-pyridinyl-propionamide; cis[3-[8-Dimethylamino(3-methoxy-propyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]- propanoylamino]methyl-propionamide; cis[8-Dimethylamino(3-methoxy-propyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(2- methylsulfonyl-ethyl)-propionamide; cis[8-Dimethylamino(3-methoxy-propyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]-N-(2- hydroxy-ethyl)-propionamide; cisDimethylamino(3-methoxy-propyl)[3-oxo(3-oxo-piperazinyl)-propyl]phenyl-1,3- diazaspiro[4.5]decanone; cis-(2R)[3-[8-Dimethylamino(3-methoxy-propyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]- propanoyl]-pyrrolidinecarboxylic acid amide; cis-N-(Carbamoyl-methyl)[8-dimethylamino(3-methoxy-propyl)oxophenyl-1,3- diazaspiro[4.5]decanyl]-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-pyridinyl-propionamide; cis[1-(Cyclobutyl-methyl)(ethyl-methyl-amino)oxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2- dimethyl-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2- dimethyl-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]- propionamide; cis[1-(Cyclobutyl-methyl)[methyl-(2-methyl-propyl)-amino]oxophenyl-1,3- diazaspiro[4.5]decanyl]-N-methyl-propionamide; cis[1-(Cyclobutyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-N-methyl- propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-pyrimidinyl-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-methyl-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-(2-methoxy-ethyl)-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-(2-hydroxy-ethyl)-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-(oxetanyl)-propionamide; cis-N-(Carbamoyl-methyl)[1-(cyclobutyl-methyl)dimethyl-aminooxophenyl-1,3- diazaspiro[4.5]decanyl]-2,2-dimethyl-propionamide; cis-N-(Carbamoyl-methyl)[1-(cyclobutyl-methyl)methylaminooxophenyl-1,3- diazaspiro[4.5]decanyl]-2,2-dimethyl-propionamide; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-2,2-dimethyl-propionamide; cis[1-[(1-Hydroxy-cyclobutyl)-methyl]methylaminooxophenyl-1,3-diazaspiro[4.5]decan yl]-N-(oxetanyl)-propionamide; cis[1-[(1-Hydroxy-cyclobutyl)-methyl]methylaminooxophenyl-1,3-diazaspiro[4.5]decan yl]-2,2-dimethyl-propionamide; cis[8-(Ethyl-methyl-amino)oxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2-dimethyl- propionamide; cis[8-(Ethyl-methyl-amino)methyloxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2-dimethyl- propionamide; cis-2,2-Dimethyl(8-methylaminooxophenyl-1,3-diazaspiro[4.5]decanyl)-propionamide; cis(8-Ethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl)-2,2-dimethyl-propionamide; cis(8-Dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl)-2,2-dimethyl-propionamide; cis[1-(Cyclobutyl-methyl)ethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2-dimethyl- propionamide; cis[8-Dimethylamino(oxetanyl-methyl)oxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2- dimethyl-propionamide; cis[1-(Cyclopropyl-methyl)dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl]-2,2- dimethyl-propionamide; cis[8-(Ethyl-methyl-amino)[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3- diazaspiro[4.5]decanyl]-2,2-dimethyl-propionamide; cisDimethylamino(2,2-dimethylmorpholinyloxo-propyl)[(1-hydroxy-cyclobutyl)- methyl]phenyl-1,3-diazaspiro[4.5]decanone; cis[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3-diazaspiro[4.5]decan yl]-N-(2-hydroxy-ethyl)-2,2-dimethyl-propionamide; cis[1-[(1-Cyano-cyclobutyl)-methyl]dimethylaminooxophenyl-1,3-diazaspiro[4.5]decan yl]-2,2-dimethyl-propionamide; cisDimethylamino[3-(1,1-dioxo-[1,4]thiazinanyl)-2,2-dimethyloxo-propyl][(1-hydroxy- cyclobutyl)-methyl]phenyl-1,3-diazaspiro[4.5]decanone; TRANS[8-Dimethylamino[(1-hydroxy-cyclobutyl)-methyl]oxophenyl-1,3- diazaspiro[4.5]decanyl]-2,2-dimethyl-propionamide TRANS(8-Dimethylaminooxophenyl-1,3-diazaspiro[4.5]decanyl)-2,2-dimethyl- propionamide; cis[1-(Cyclopropyl-methyl)dimethylamino(3-fluorophenyl)oxo-1,3-diazaspiro[4.5]decan yl]-N,N-dimethyl-propionamide; cis[1-(Cyclopropyl-methyl)dimethylamino(3-fluorophenyl)oxo-1,3-diazaspiro[4.5]decan yl]-2,2-dimethyl-propionamide; cis((1-(cyclopropylmethyl)(dimethylamino)oxophenyl-1,3-diazaspiro[4.5]decan yl)methyl)cyclopropanecarboxamide; cis((1-(cyclopropylmethyl)(dimethylamino)oxophenyl-1,3-diazaspiro[4.5]decan yl)methyl)oxetanecarboxamide; cis(1-(cyclopropylmethyl)(methylamino)oxophenyl-1,3-diazaspiro[4.5]decanyl)-2,2- dimethylpropanamide; cis(1-(cyclopropylmethyl)(dimethylamino)oxophenyl-1,3-diazaspiro[4.5]decan yl)propanamide; cis(8-(dimethylamino)((1-fluorocyclopropyl)methyl)oxophenyl-1,3-diazaspiro[4.5]decan yl)-2,2-dimethylpropanamide and the physiologically acceptable salts thereof. 14. Use of the compound according to any one of the preceding claims for the manufacture of a medicament for treating pain. 15. A medicament comprising a compound according to any one of claims 1 to 13.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16151011 | 2016-01-13 | ||
| PCT/EP2017/025004 WO2017121646A1 (en) | 2016-01-13 | 2017-01-13 | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ745187A NZ745187A (en) | 2024-03-22 |
| NZ745187B2 true NZ745187B2 (en) | 2024-06-25 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4328227A1 (en) | Nucleoside compound and application thereof in the treatment of feline infectious peritonitis | |
| AU2019331993B2 (en) | Highly active sting protein agonist compound | |
| BR112020001299A2 (en) | heteroaryl piperazine derivatives, method of preparing them and their use in medicine | |
| CN112778301A (en) | Tetrahydropyridopyrimidine inhibitor and preparation method and application thereof | |
| JP5265518B2 (en) | Dimers of artemisinin derivatives, their preparation and their therapeutic use | |
| AU758100B2 (en) | Semi-synthetic ecteinascidins | |
| EP4159738A1 (en) | Macrocyclic jak inhibitor and uses thereof | |
| AU2021239828A1 (en) | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | |
| AU2021353722B2 (en) | Benzamide compound and use thereof | |
| ES3002743T3 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP1725102A1 (en) | Hiv integrase inhibitors | |
| WO2021124155A1 (en) | Benzimidazole derivatives | |
| AU2005233382C1 (en) | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | |
| AU2019227250B2 (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| NZ745187B2 (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| NZ745187A (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| KR20240168367A (en) | Compounds, Compositions and Methods | |
| WO2008149244A2 (en) | Compositions and methods comprising analogues of radicicol a | |
| AU2021309147A1 (en) | Codrug that disintegrates in intestine, preparation therefor, and use thereof | |
| ES2927324T3 (en) | Pyrrolo[2,3-d]pyrimidine compounds or their salts | |
| NZ745185A (en) | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| NZ745185B2 (en) | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| NZ745186B2 (en) | 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| NZ745186A (en) | 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| NZ784118A (en) | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |